- Home
- GRRR vs INTS Comparison
GRRR vs INTS Comparison
Compare GRRR & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRRR
- INTS
- Stock Information
- Founded
- GRRR 2001
- INTS 2012
- Country
- GRRR United Kingdom
- INTS United States
- Employees
- GRRR N/A
- INTS N/A
- Industry
- GRRR Computer Software: Prepackaged Software
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- GRRR Technology
- INTS Health Care
- Exchange
- GRRR Nasdaq
- INTS Nasdaq
- Market Cap
- GRRR 47.8M
- INTS 43.7M
- IPO Year
- GRRR N/A
- INTS 2023
- Fundamental
- Price
- GRRR $4.35
- INTS $2.70
- Analyst Decision
- GRRR Buy
- INTS Strong Buy
- Analyst Count
- GRRR 1
- INTS 2
- Target Price
- GRRR $9.00
- INTS $8.50
- AVG Volume (30 Days)
- GRRR 415.2K
- INTS 16.4K
- Earning Date
- GRRR 11-29-2024
- INTS 11-13-2024
- Dividend Yield
- GRRR N/A
- INTS N/A
- EPS Growth
- GRRR N/A
- INTS N/A
- EPS
- GRRR 2.28
- INTS N/A
- Revenue
- GRRR $78,940,347.00
- INTS N/A
- Revenue This Year
- GRRR $15.59
- INTS N/A
- Revenue Next Year
- GRRR $20.59
- INTS N/A
- P/E Ratio
- GRRR $1.91
- INTS N/A
- Revenue Growth
- GRRR 424.97
- INTS N/A
- 52 Week Low
- GRRR $2.09
- INTS $2.15
- 52 Week High
- GRRR $13.00
- INTS $11.44
- Technical
- Relative Strength Index (RSI)
- GRRR 52.57
- INTS 30.58
- Support Level
- GRRR $3.71
- INTS $2.80
- Resistance Level
- GRRR $4.79
- INTS $3.30
- Average True Range (ATR)
- GRRR 0.31
- INTS 0.21
- MACD
- GRRR -0.05
- INTS -0.02
- Stochastic Oscillator
- GRRR 59.26
- INTS 22.22
About GRRR Gorilla Technology Group Inc. Ordinary shares
Gorilla Technology Group Inc is primarily engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.